Cell and Gene Therapy Market Size, Trends & Forecast 2034

According to Expert Market Research, the global cell and gene therapy market reached a value of USD 17.40 billion in 2024. The market is expected to grow at a robust CAGR of 23.17% during the forecast period of 2025 to 2034, reaching approximately USD 139.83 billion by 2034. The growth is propelled by strong regulatory support from health authorities, a surge in clinical trial activities, and increased investment by biotechnology companies in advanced therapeutic development. The approval of breakthrough therapies and rising demand for personalized medicine are also accelerating the expansion of the global cell and gene therapy industry. As precision medicine becomes more central to healthcare delivery, these innovative treatment modalities are revolutionizing how chronic, rare, and genetic diseases are managed.

Understanding Cell and Gene Therapy

Cell therapy involves the transplantation of human cells to replace or repair damaged tissues and cells, whereas gene therapy involves the insertion or alteration of genes within a patient’s cells to treat or prevent disease. These therapies are designed to provide long-term, and in some cases, curative treatment for conditions that are difficult or impossible to treat using traditional methods. They are especially promising in treating cancer, rare genetic disorders, neurological conditions, and inherited retinal diseases.

Unlike conventional drugs, cell and gene therapies offer highly targeted treatment, potentially transforming the outcomes for patients suffering from previously untreatable conditions. As more therapies enter the pipeline and receive regulatory approvals, the market is expected to witness a significant transformation in the coming years.

Key Market Drivers

Regulatory Advancements and Support
Global regulatory bodies such as the U.S. FDA, EMA, and Japan’s PMDA have established specialized frameworks and fast-track approval processes for cell and gene therapies. The introduction of designations like Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Status provides incentives for development and speeds up market entry.

Growth in Clinical Trials
A growing number of clinical trials focused on advanced therapies is a major contributor to market expansion. Researchers and companies are exploring the therapeutic potential of genetically modified cells, CAR-T cell therapies, stem cell treatments, and CRISPR gene editing across a wide array of diseases.

Rising Demand for Personalized Medicine
The increasing focus on personalized medicine is boosting the demand for cell and gene therapies, which offer customized treatment based on a patient’s genetic makeup. These therapies are particularly effective for rare diseases and conditions with limited treatment options.

Increasing Prevalence of Genetic and Chronic Disorders
The global rise in genetic diseases, cancer, and chronic conditions such as hemophilia, sickle cell anemia, and Parkinson’s disease is driving the demand for more effective and lasting treatment options. Cell and gene therapies are showing high efficacy in addressing the root causes of these diseases.

Technological Innovation in Vector Development and Delivery Systems
Advances in viral and non-viral vector technologies, such as adeno-associated virus (AAV) vectors and lipid nanoparticles, are improving the safety, efficiency, and scalability of gene delivery systems. This is enabling wider application and accessibility of gene-based therapies.

Access a Free Sample Report with Table of Contents: Click Here

Market Segmentation

Regional Insights

North America
North America dominates the global cell and gene therapy market due to the presence of major biopharmaceutical companies, well-developed healthcare infrastructure, and strong regulatory frameworks. The U.S. FDA’s proactive stance on regenerative therapies has fostered innovation and early adoption. The growing number of approved therapies and partnerships between biotech firms and academic institutions is accelerating market growth in the region.

Europe
Europe holds a significant market share, driven by increasing investment in regenerative medicine and favorable reimbursement policies in countries like Germany, France, and the UK. The European Medicines Agency (EMA) supports advanced therapy medicinal products (ATMPs), and several products have already received approval under these guidelines.

Asia-Pacific
Asia-Pacific is expected to witness the fastest growth during the forecast period. Countries like China, Japan, and South Korea are investing heavily in biotechnology infrastructure, research capabilities, and regulatory streamlining. The rapidly expanding patient base and rising healthcare expenditures are also contributing to market expansion in this region.

Latin America
Latin America is emerging as a potential market, supported by increasing awareness, better healthcare access, and the gradual adoption of novel treatment approaches. Countries such as Brazil and Mexico are making progress in clinical research and therapy adoption, particularly in oncology.

Middle East and Africa
While still in the nascent stage, the Middle East and Africa are gaining traction due to rising healthcare investments and collaborative research initiatives. Governments in the UAE, Saudi Arabia, and South Africa are looking to strengthen biotech sectors and enhance access to advanced treatments.

Market Challenges

Despite the promising outlook, several challenges impact the widespread adoption of cell and gene therapies. These include:

• High development and manufacturing costs
• Complex regulatory requirements across regions
• Scalability issues and supply chain limitations
• Limited skilled workforce in gene editing and cell engineering
• Reimbursement challenges and high therapy prices

Efforts are being made to address these challenges through increased collaboration, public-private partnerships, and innovations in scalable manufacturing processes.

Key Players

• Amgen Inc.
• Novartis AG
• Pfizer Inc.
• Bluebird Bio, Inc.
• Castle Creek Pharmaceutical Holdings
• Bristol-Myers Squibb
• Kite Pharma, Inc.
• Vericel Corporation Inc.
• Kolon TissueGene Inc.
• Vertex Pharmaceuticals, Inc.
• Spark Therapeutics, Inc.
• CORESTEM Inc.
• Biogen Inc.
• Dendreon Pharmaceuticals LLC.
• JCR Pharmaceuticals Co. Ltd.

These companies are actively developing pipelines in gene and cell-based therapies, with multiple products already in the commercial and late-stage clinical pipeline.

Future Trends in the Cell and Gene Therapy Market

Commercialization of Pipeline Therapies
A surge in pipeline approvals is expected over the next decade, particularly in areas such as hematologic malignancies, neurodegenerative disorders, and inherited genetic diseases.

Expansion of Allogeneic Cell Therapies
Unlike autologous therapies, allogeneic (off-the-shelf) cell therapies offer faster delivery and cost advantages. Advances in immune evasion techniques are enabling safe development of allogeneic treatments.

CRISPR and Gene Editing Revolution
Gene editing tools like CRISPR/Cas9 are transforming how diseases are treated at the genomic level. With growing safety and efficacy profiles, these tools are expected to become mainstream in future therapies.

Advanced Manufacturing Platforms
Efforts are underway to automate and scale the manufacturing of cell and gene therapies using modular, closed-loop systems to reduce costs and enhance quality control.

AI and Data Integration in Therapy Development
Artificial intelligence is being increasingly used to identify therapeutic targets, optimize vectors, and streamline clinical trial designs, significantly accelerating the development cycle.

Frequently Asked Questions (FAQs)

What is the projected value of the global cell and gene therapy market by 2034?
The global market is expected to reach USD 139.83 billion by 2034, growing at a CAGR of 23.17% from USD 17.40 billion in 2024.

Which conditions are treated using cell and gene therapy?
Cell and gene therapies are used to treat cancer, genetic disorders, cardiovascular diseases, neurological conditions, and rare inherited diseases.

What is the difference between cell therapy and gene therapy?
Cell therapy involves the transfer of cells into a patient to repair or replace damaged tissue, while gene therapy involves modifying a patient’s genes to treat or prevent disease.

Which region dominates the cell and gene therapy market?
North America leads the global market, followed by Europe and Asia-Pacific, with high adoption, innovation, and regulatory support.

Who are the leading companies in the cell and gene therapy industry?
Key players include Novartis, Gilead, Spark Therapeutics, Bluebird Bio, CRISPR Therapeutics, and Bristol-Myers Squibb, among others.

Media Contact:

Company Name: Claight Corporation
Email: sales@expertmarketresearch.com
Toll Free Number: +1-415-325-5166 | +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: https://www.expertmarketresearch.com